• broken image


    How does COVIX-19 differ from other tests?

  • COVIX-19 Antibody vs. RT-PCR Testing

    COVIX-19 is a qualitative analysis of whole blood samples to determine the presence of COVID-19 specific antibodies that may be present in a currently infected, or past infected individual. This varies from RT-PCR testing, which looks for cDNA or the presence of specific viral RNA that may indicate COVID-19 infection.


    It is not scientifically accurate to compare the results from COVIX-19 and RT-PCR testing, as they both look for different signs of viral infection. We can, however, compare different attributes of the deployability of the tests, as we have below.

    COVIX-19 Antibody Testing

    • Looks for antibodies specific to COVID-19
    • Provides rapid and reliable results
    • Does not require any additional hardware
    • Provides reliable results based on the easy administration of the test
    • Is proven up to 98.5% accurate

    RT-PCR Testing

    • Looks for cDNA and presence of specific viral RNA
    • Lab processing and wait times are required
    • Additional hardware required for results
    • Reliability varies on many factors
    • Up-to 80% FALSE POSITIVE results
  • COVIX-19 Rapid Antibody Test Kit Explained

    COVIX-19 looks specifically for COVID-19 antibodies in the blood. There are two types of COVID-19 specific antibodies that COVIX-19 detects: IgG and IgM.


    Where COVIX-19 differs from standard testing options available is simple. COVIX-19 looks for an immune system response against COVID-19. It does not look for COVID-19 viral material. It is not accurate to compare COVIX-19 to traditional RT-PCR testing from a scientific perspective, as both look for two different signs of infection.


    The easiest explanation for this is the analogy "Where there's smoke, there's fire." COVIX-19 looks for the "smoke" specifically from the fire (a byproduct of the infection), whereas RT-PCR testing looks for the "ash" (a typically assumed byproduct of the fire).


    There is no rapidly deployable, readily available, and commercially viable test that looks specifically for COVID-19 virus cells.

    Immunoglobulin M (IgM) Antibodies

    IgM antibodies are created by a body's immune system during the early to mid phases of contracting a virus. In this case, COVIX-19 looks specifically for COVID-19 IgM antibodies during the early to mid phase of infection.


    These IgM antibodies are typically first detectable on day 1 to 3 of symptomatic infection.


    IgM antibodies usually remain detectable up to 28-days from the onset of the first symptoms.

    Immunoglobulin G (IgG) Antibodies

    IgG antibodies are the "second line of defence" after IgM antibodies. COVIX-19 typically detects these antibodies during the mid to late stage infection of COVID-19.


    IgG antibodies are usually detectable by COVIX-19 around 7 days post-symptomatic infection, and are responsible for long-term immunity and immunological memory.


    IgG antibodies usually remain detectable in whole blood samples longer than 45 days post-infection from COVID-19